CD274 and heart failure: A meta-analysis of clinical trials of PD-1 inhibitors (nivolumab and pembrolizumab) and PD-L1 inhibitors (atezolizumab, avelumab and durvalumab) for treatment of non-small cell lung cancer also reported lower cardiovascular adverse event rates (1% for cardiorespiratory arrest, 2% for heart failure, 1% for myocardial infarction, and 2% for strokes) [25].